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Abstract
Background:  Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF MS) is a powerful tool for rapidly generating high-throughput protein profiles from a
large number of samples. However, the events that occur between the first and last sample run are
likely to introduce technical variation in the results.
Methods: We fractionated and analyzed quality control and investigational serum samples on 3
Protein Chips and used statistical methods to identify poor-quality spectra and to identify and
reduce technical variation.
Results: Using diagnostic plots, we were able to visually depict all spectra and to identify and
remove those that were of poor quality. We detected a technical variation associated with when
the samples were run (referred to as batch effect) and corrected for this variation using analysis of
variance. These corrections increased the number of peaks that were reproducibly detected.
Conclusion: By removing poor-quality, outlier spectra, we were able to increase peak detection,
and by reducing the variance introduced when samples are processed and analyzed in batches, we
were able to increase the reproducibility of peak detection.
Background
Surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF MS) allows users to
generate protein expression data rapidly from a large
number of samples and has been used increasingly to
identify diagnostic biomarkers of cancer [1-3], mental ill-
ness [4,5], and neurological disorders [6,7]. However, as
with any analytic technique, its results must be reproduc-
ible if one is to have confidence in them.
Several challenges to implementing SELDI-TOF MS in
routine clinical diagnostics have already been overcome
[8-10]. These include challenges pertaining to biologic
samples such as the characterization of sample donors
(e.g., by age, sex, fasting status, diurnal rhythm) [11]; sam-
ple collection and handling [12,13]; and the effects of
freezing, thawing, and storage on specimen stability [14].
Parameters of the SELDI-TOF MS technique that have
been assessed range from its sample-processing and
robotic-handling systems to its application of the energy-
absorbing matrix [15-17]. Finally, many aspects of the
technique designed to improve the calibration and quality
of the spectra [10,18-21] and of peak detection and quan-
tification [22-24] have made SELDI-TOF MS one of the
most promising protein biomarker discovery methods.
Published: 5 September 2007
Proteome Science 2007, 5:14 doi:10.1186/1477-5956-5-14
Received: 25 June 2007
Accepted: 5 September 2007
This article is available from: http://www.proteomesci.com/content/5/1/14
© 2007 Whistler et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
Page 2 of 9
(page number not for citation purposes)
Even though a variety of software packages can be used to
analyze SELDI-TOF MS data, few are effective in averaging
replicate spectra or identifying poor-quality spectra
[25,26], and none are capable of analyzing and adjusting
for the variation introduced when samples are processed
and analyzed in batches. We demonstrate that conven-
tional statistical approaches can be used to identify outly-
ing spectra and correct for batch variation, as well as to
increase the number of peaks detected by SELDI-TOF MS
and improve the reproducibility of peak detection.
Results
To identify and remove poor-quality spectra, we assessed
the degree of linear relationship among all spectra in each
data set (a ProteinChip-fraction combination). We then
generated a pair-wise similarity matrix using the Pearson
correlation coefficient on normalized intensity values of
each spectrum. To visually depict the data, we drew a diag-
nostic plot of 1 minus the mean (1-mean) of Pearson cor-
relation coefficients (x-axis) against the range of
correlation coefficients (y-axis) (Figure 1). By comparing
the results depicted in these diagnostic plots to other eval-
uation methodologies, such as principal component anal-
ysis of the processed spectra or signal to noise (SN) ratios,
and by comparing the number of peaks in each spectrum
with the average number of peaks for all spectra in the
data set, we established cut-off values of 1-mean > 0.2 for
QC spectra and > 0.4 for specimen spectra.
Variation in analytic results is introduced when samples
are processed and analyzed in different batches. To exam-
ine the extent of this batch effect, we used the nonpara-
metric Kruskal-Wallis test to compare the normalized
peak intensities in the spectra within a batch to the same
peak (by mass-to-charge (m/z) value) in the spectra from
all other batches. Our null hypothesis was that intensity
means would be identical for each peak across the differ-
ent batches. Using a corrected p-value of < 0.005 to calcu-
late the number of peaks that were different in at least one
batch, we found a statistically significant batch effect in at
least 50% of peaks for each ProteinChip-fraction combi-
nation (Figure 2).
We used a 2-way analysis of variation (ANOVA) model to
explore batch effect variation in the QC sample and a 3-
way ANOVA model to explore batch effect variation in the
investigational samples. The batch from which spectra
were processed was the largest source of variation in both
the QC and the investigational samples (Figure 2). The
range of the F ratio (or signal-to- noise ratio) was 4 to 14
for the QC sample, much lower than the 2 to 34 F ratio
range for the investigational samples. The CM10 low-
stringency (CMLS) fractions 1 to 4 (F1-F4) and the IMAC
F1 and F3 ProteinChips showed the lowest batch variance,
with QC and investigational samples having similar F
ratios (Figure 2).
As described in the Methods section, we used the Batch
Remover tool (Partek Genomics Suite) to reduce the
effects of batch variation. Hierarchical clustering of spec-
tra in each data set showed that before we used the Batch
Removal tool, each batch clustered as a distinct node (Fig-
ure 3 for CMLS-F4-QC). In fact, 2 nodes were apparent in
all data sets, one for batches run prior to unexpected
instrument maintenance being done (batches A through
F) and one for batches run after such maintenance was
done (batches G through K). After we applied the Batch
Removal tool, however, we observed no clustering by
batch (Figure 3).
We assessed the quality of each spectrum by using the
Pearson correlation coefficient to compare the 11,876
intensity measures of each spectrum. Using the cut-off cri-
teria we established of 1-mean > 0.2 for QC spectra and >
0.4 for specimen spectra, we obtained very similar results
if we used peak intensities (less than 100 values per spec-
trum) to generate the correlation matrix. Before the outlier
spectra and batch effect variance were removed, the corre-
lation coefficients ranged from 0.75 to 0.95 in each full
data set (Table 1A). Removing poor-quality spectra
improved the correlations, 0.88 to 0.96 (Table 1B) as did
removing the batch effect, 0.95 to 0.99 (Table 1C). Dupli-
cate spectra from individual samples showed a high
degree of reproducibility as demonstrated by a median
Pearson correlation coefficient of 0.98 for the 207 pairs of
spectra in the CMLS-F4 data set. Results for the other data
sets were similar (results not shown).
To measure the reproducibility, we calculated the coeffi-
cient of variation for the peak intensities of all spectra in
each QC sample data set (Table 1). Similar data is availa-
ble for the investigational samples [see Additional file 1].
The removal of low-quality spectra generally improved
the number of peaks common to all spectra in that data
set and reduced the average CV for the full spectrum
(Table 1B). Batch removal produced a more dramatic
effect (Table 1C): the number of peaks remained the
same, but the average CV improved as did the number of
peaks in each data set with a CV < 30% (Table 1). For
example, the CMLS_F5 QC serum data set started with 66
spectra with 54 peaks present; the average CV for speci-
mens in this set was 70% (range: 11–274%, Table 1A).
Using the diagnostic plot criteria, we removed two spec-
tra, thereby reducing the CV range to 10–48% and the
average CV to 24% (Table 1B). Removing the batch effect
technical variance further reduced the CV range to 6–31%
and the average CV to 13% (Table 1C). We obtained sim-
ilar results with the specimen data sets [see Additional fileProteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
Page 3 of 9
(page number not for citation purposes)
1]. For all data sets, the CV for m/z values were within the
0.3% reported in the literature [19].
Discussion
Even though SELDI-TOF MS is designed as a high-
throughput automated assay, large studies involving
many biological samples are often divided into batches
that are analyzed over several days to weeks. To detect any
variability that may occur, analysts process pooled human
serum (QC samples) with the study samples. In this study,
we used an ANOVA model to assess technical variance in
peak intensities that could be introduced by differences
among sample batches, variations in the spot position of
each sample on the ProteinChip, and variations in the
ProteinChip array. We found that batch differences
accounted for the largest source of technical variability in
each data set, with variations in spot position and Protein-
Chip array contributing little. Therefore, any analysis that
ignores the variation associated with processing samples
in different batches leaves a considerable amount of noise
in the data. The balanced design of the experiments we
conducted allowed us to reliably estimate the batch effect
and then to remove that effect using the Partek Batch
Remover (based on a mixed-model ANOVA). As only
technical factors were included in the ANOVA model, the
peak intensity data can then be used in further statistical
analyses.
Hong et al. [27] identified the correlation matrix as an
effective metric for identifying lower quality spectra. How-
ever, we found that this approach was less effective when
used to establish one cut-off value for several large data
sets. In an attempt to automate our decisions on which
spectra should be included in our analysis, we drew on
our knowledge of microarrays and presented our data in
diagnostic plots [28] (Figure 1). The results we obtained
using diagnostic plots to assess poor spectrum quality
compared favourably with assessments based on visual
inspection and normalization factors >2 standard devia-
tions from the mean (as recommended by Ciphergen Bio-
systems, Freemont, USA). Our use of statistical measures
to assess spectrum quality allowed us to automatically
remove even more poor-quality spectra. There are other
measures that could be considered in determining data
quality, for example peak resolution [18,19], however the
software packages used in this analysis did not determine
this parameter.
QC data sets represent the same pooled serum sample run
with each batch of investigational sera. This directly eval-
uates the repeatability of measurements and a more strin-
gent cut off value (1-mean > 0.2) is used with the QC data
sets compared to the investigational data sets. The repeat-
ability is expected to be much higher in the QC data sets.
Good performance should be associated with low coeffi-
cients of variation for the peak intensities, as the data are
all derived from the same pooled reference serum. Table 1
illustrates the improvements in data quality and repro-
ducibility resulting from the removal of outlying, poor-
quality spectra and the removal of the technical batch
effect. The average CVs for all data sets (except H50-F1)
were ≤ 20% when all peaks were considered rather than
just 3 to 7 major peaks as reported in some studies
[29,30]; furthermore, more than 90% of all peaks in each
data set, other than H50-F1, had peak intensity CVs <
30%.
Conclusion
In this study, we used a diagnostic plot to detect and dis-
card low-quality spectra. This method was easy to imple-
ment and effective in detecting outlier spectra. Our use of
the model-based ANOVA to account for the technical var-
iance introduced by batch processing of spectra further
improved the data quality.
Diagnostic plot generated from a Pearson correlation matrix  of 66 QC spectra from the CMLS-F4 data set Figure 1
Diagnostic plot generated from a Pearson correla-
tion matrix of 66 QC spectra from the CMLS-F4 data 
set. A cut-off value of 1-Mean of Pearson correlation coeffi-
cient > 0.2 was used to exclude spectra from the QC analysis 
(blue line). In this data set, 2 QC sample spectra were above 
this cut-off (colored blue) and therefore were removed prior 
to further processing. For spectra from the investigational 
data set, a 1-Mean > 0.4 was used for all ProteinChip-Frac-
tion combinations.Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
Page 4 of 9
(page number not for citation purposes)
Methods
Samples
A reference or QC sample was prepared by pooling serum
collected in Vacutainer tubes with no additives from 10
donors. This was processed, aliquoted and frozen in the
same manner as study subject samples. Serum samples
from 207 subjects (referred to as investigational sera) were
collected during a clinical study of Chronic Fatigue Syn-
drome in Wichita Kansas [31].
Serum fractionation
All of the experimental protocols were performed by a sin-
gle laboratorian.
To reduce sample complexity and increase the number of
protein peaks detected, we performed anion exchange
fractionation using the Expression Difference Mapping™
Kit – Serum Fractionation (Ciphergen Biosystems Inc.,
Fremont, CA, USA) the robotic Biomek 2000 liquid han-
dling system (Beckman Coulter, Fullerton, CA, USA). We
collected six different fractions – pH 9 (F1), pH 7 (F2), pH
5 (F3), pH 4 (F4), pH 3 (F5) and organic (F6) – from
investigational serum samples that were fractionated in
11 batches over a period of 7 months. Twenty investiga-
tional samples and 3 QC samples were processed in each
batch and then frozen at -80°C. For each batch, we ana-
lyzed fractions in the same order and kept freezing times
(2 to 11 days) and processing conditions constant.
Protein expression profiling
Aliquots of each fraction were bound in duplicate with a
randomized ProteinChip/spot position allocation scheme
to 3 different types of ProteinChip arrays: IMAC-Cu
(metal binding), H50 (hydrophobic chemistry) and two
CM10 (anionic chemistry) ProteinChip arrays. One for a
high stringency (HS) wash using 50 mM HEPES, pH7 per-
formed before sample application to allow selective bind-
ing of proteins, and one for low stringency (LS) wash, 0.1
M sodium acetate pH4, performed before sample applica-
tion. From previous studies [32], we know that F2 is not
Sources of technical variation for the QC (left) and Investigational (right) data sets prior to the Partek Batch Removal process Figure 2
Sources of technical variation for the QC (left) and Investigational (right) data sets prior to the Partek Batch 
Removal process. A plot of the average F ratio (the signal-to-noise ratio) produced when we applied the ANOVA model 
(Batch and Spot) to the QC data sets (left), and the Investigational data set (right) which also included ProteinChip lot number 
(Array). Analysis was performed on spectra after removal of outlier spectra, prior to technical effect batch removal. Batch 
effect is the largest contributor to variance. The numbers above each group indicate the percentage of peaks that were differ-
ent in at least one batch (p > 0.005) as determined by the Kruskal-Wallis test. The QC data set is derived from a pooled serum 
sample so no. After batch removal, none of the peaks were significantly different.Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
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Dendrograms from hierarchical cluster analysis of spectra from CMLS-F4-QC data set labelled by batch, processed before  (left) and after (right) Partek Batch Removal Figure 3
Dendrograms from hierarchical cluster analysis of spectra from CMLS-F4-QC data set labelled by batch, proc-
essed before (left) and after (right) Partek Batch Removal. QC spectra peak intensities from different points in the 
analytical process were used to generate dendrograms from hierarchical cluster analysis (Spearman rank dissimilarity metric 
with average linkage). Each spectrum was labeled for the batch in which it was processed (A through K). The dendrogram on 
the left is from analysis of spectra before Partek Batch Remover was applied to the data set. Spectra cluster in nodes according 
to the batch in which they were processed. Two large clusters are evident. One with spectra from batches A through F. The 
second covering batches G through K. An unanticipated instrument adjustment had to be made between the sixth and seventh 
batch, which is noticed in the analysis. The dendrogram on the right shows the hierarchical cluster analysis of the same data 
after Partek Batch Remover was used to reduce the contribution of batch effect technical variance. Spectra no longer cluster 
by batch in which they were processed, and spectra from before and after the instrument maintenance are inter-mingled 
across the 2 major nodes.Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
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Table 1: Summary data showing stages in the quality assessment of QC sample spectra.
Analysis Step QC Data Set Pearson Correlation Coefficient 
(Grand Mean ± Std Dev)
No. spectra No peaks Coefficient of Variation (%)
Low High Average % Peaks CV < 30%
A CMHS_F3 0.834 ± 0.225 66 58 15.1 199.2 44.8 34
CMHS_F4 0.829 ± 0.135 66 37 14.1 84.7 37.9 27
CMLS_F1 0.946 ± 0.038 66 68 8.0 48.1 22.5 82
CMLS_F3 0.851 ± 0.142 66 72 7.8 50.1 26.3 69
CMLS_F4 0.918 ± 0.110 66 54 9.8 53.7 24.1 76
CMLS_F5 0.879 ± 0.146 66 54 10.5 274.4 32.9 70
CMLS_F6 0.904 ± 0.173 66 57 9.2 47.6 26.4 61
H50_F1 0.948 ± 0.065 66 35 17.4 125.1 45.6 37
H50_F3 0.844 ± 0.189 66 78 8.3 233.0 28.6 67
H50_F4 0.891 ± 0.084 66 69 11.8 110.7 28.9 71
H50_F6 0.790 ± 0.256 66 47 16.9 155.5 43.9 36
IMAC_F1 0.939 ± 0.038 66 66 9.5 54.8 29.9 59
IMAC_F3 0.884 ± 0.112 66 57 13.1 65.6 34.1 39
IMAC_F4 0.911 ± 0.080 66 50 14.3 48.3 27.4 68
IMAC_F6 0.728 ± 0.265 66 55 9.7 66.8 35.4 36
B CMHS_F3 0.940 ± 0.037 58 53 9.8 86.0 33.2 57
CMHS_F4 0.878 ± 0.085 59 41 12.1 89.1 34.7 44
CMLS_F1 0.946 ± 0.038 66 68 8.0 48.1 22.5 82
CMLS_F3 0.911 ± 0.059 57 75 7.2 45.4 23.9 77
CMLS_F4 0.941 ± 0.049 64 55 9.7 41.8 21.9 84
CMLS_F5 0.910 ± 0.060 63 52 10.4 47.8 24.2 77
CMLS_F6 0.935 ± 0.055 65 71 9.2 50.6 24.6 69
H50_F1 0.961 ± 0.037 65 83 14.3 131.2 49.4 24
H50_F3 0.922 ± 0.055 58 78 8.2 65.3 21.6 82
H50_F4 0.905 ± 0.068 63 69 8.5 111.8 26.9 74
H50_F6 0.922 ± 0.057 48 46 14.8 169.1 36.0 43
IMAC_F1 0.939 ± 0.038 66 66 9.5 54.8 29.9 59
IMAC_F3 0.925 ± 0.045 61 60 12.5 58.3 31.8 43
IMAC_F4 0.921 ± 0.061 65 50 14.2 47.4 26.9 68
IMAC_F6 0.929 ± 0.041 16 60 7.0 46.2 23.6 70
C CMHS_F3 0.980 ± 0.018 58 53 8.1 50.4 19.1 92
CMHS_F4 0.971 ± 0.027 59 41 5.5 24.6 16.2 100
CMLS_F1 0.975 ± 0.026 66 68 5.3 30.0 15.1 100
CMLS_F3 0.961 ± 0.052 57 75 5.2 25.7 13.9 100
CMLS_F4 0.972 ± 0.039 64 55 5.9 26.2 14.4 100
CMLS_F5 0.979 ± 0.018 63 52 5.8 30.8 13.0 98
CMLS_F6 0.975 ± 0.024 65 71 5.2 42.3 15.8 96
H50_F1 0.990 ± 0.012 65 83 10.6 81.3 26.5 72
H50_F3 0.982 ± 0.012 58 78 5.8 40.4 13.5 95
H50_F4 0.977 ± 0.019 63 69 5.0 50.9 13.7 94
H50_F6 0.971 ± 0.028 48 46 7.1 51.8 17.1 91
IMAC_F1 0.976 ± 0.197 66 66 7.1 43.2 19.5 92
IMAC_F3 0.968 ± 0.045 61 60 8.6 33.5 19.3 95
IMAC_F4 0.945 ± 0.055 65 50 10.2 39.7 20.8 88
IMAC_F6 0.989 ± 0.009 16 60 2.5 29.0 7.7 100
Pearson Correlation Coefficients were calculated on the entire spectrum prior to peak detection, the coefficient for the entire dataset is reported 
(Grand statistic). The coefficient of variation (CV) is calculated on all peak intensities.
(A) All spectra in each QC sample data sets
(B) Spectra remaining after passing diagnostic plot cut-off of 1-Mean r < 0.2
(C) Spectra after Partek Batch Removal.Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
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particularly informative, and F5 has many overlapping
peaks present in F4 and/or F6. Therefore, we did not run
these fractions in this study.
For each ProteinChip array, the relevant QC fraction was
present on one spot position. The details of ProteinChip
processing have been described previously [32]. We used
saturated sinapinic acid in 50% acetonitrile/0.5% trifluor-
oacetic acid as matrix and applied it using the robot. We
read the ProteinChips in a PBSIIc mass spectrometer
(Ciphergen Biosystems) using automated data collection
protocols with previously optimized conditions [32]. We
used data from the low mass range protocols (3000 to
30,000 Daltons) in our analysis and calibrated for mass
accuracy using the "all-in-one" protein standard II on
NP20 ProteinChips (Ciphergen Biosystems). The "all-in-
one" peptide standard should be used if a greater accuracy
is required at m/z < 8,000 applied with the sinapinic acid
matrix to keep data comparable.
Instrument performance and evaluation are critical to
spectrometer function and complete details of calibration,
alignment and accuracy assessments performed routinely
are fully outlined in a previous publication [32].
Using data from 15 fractions, we generated 414 investiga-
tional spectra and 66 QC spectra per ProteinChip-frac-
tion, each of which we considered a data set. We had to
make an unanticipated instrument adjustment, which
involved a preventative maintenance service, between the
sixth and seventh batches because of laboratory reloca-
tion.
Processing of spectral data sets
We used the QC serum sample to develop and evaluate
data processing procedures, which we then used in
processing data for the 207 investigational samples.
We exported raw spectrum data files for each ProteinChip-
fraction and processed them using the following calibra-
tion equation:
mz = U(a(t - t0)2 + b)( 1 )
Where m/z is the mass-to-charge ratio, U is the voltage
(20,000 for this data set), and t is the time-of-flight. For
our mass calibration, we used the values, a = 0.336302, b
= 0, and t0 = 0.09, which we obtained from the calibration
equation generated from the protein standard. The final
spectrum, from m/z 3,000 to 30,000, generated 11,876
data points. We saved the m/z and intensity values as
comma-separated values files. We used SpecAlign [33] to
pre-process each spectral data set of QC spectra (66 per
ProteinChip-fraction) and specimen spectra (414 spectra
per ProteinChip-fraction). We then followed the steps
below to process the data:
1. Smooth the data using the Savitzky-Golay filter with a
setting of 8.
2. Denoise the spectra using a wavelet transform with a
threshold setting of 0.5.
3. View baseline subtraction using a window setting of 5.
4. Subtract baseline.
5. Rescale intensity values to positive.
6. Normalize intensity values using Total Ion Current.
7. Generate an average spectrum.
8. Align spectra using the combined Fast Fourier Trans-
form (FFT)/Peak matching method on the full m/z range,
with a scale of 1, a maximum shift of 20, looking ahead by
1, and using the average as a reference.
9. Export the processed data as a single file (to be used for
correlation analysis).
10. Pick peaks with a baseline cut-off of 0.5, a window of
10, and a height ratio of 1.5
11. Export peak intensity values for all spectra in a single
file.
Statistical Analysis
We performed all statistical analysis using Partek Genom-
ics Suite software, version 6.2 (Partek Inc., St. Charles,
Missouri).
To detect outlier spectra, we used full spectrum processed
data consisting of 11,876 intensity values covering the m/
z range from 3,000 to 30,000 (the data file exported in
step 9 above). We also generated a similarity matrix using
the Pearson correlation coefficient on all combinations of
spectra within the data set. We then calculated a mean cor-
relation coefficient for each spectrum and visually
depicted the coefficients on diagnostic plots [28]. Our cut-
off criteria were 1-mean > 0.2 for the removal of QC spec-
tra and > 0.4 for the removal of spectra from investiga-
tional samples.
After the quality assessment of the spectra and prior to the
batch removal process, we used a 2-way ANOVA model to
determine the variation in the data sets. Variation in the
QC data sets attributable to the batch process (Batch, Fig-
ure 2) and to the position on the ProteinChips (Spot, Fig-Proteome Science 2007, 5:14 http://www.proteomesci.com/content/5/1/14
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ure 2) was evaluated. For the larger investigational data
sets, we used a 3-way model that also incorporated Pro-
teinChip array (Array, determined by Lot Number) as a
factor (nested in Batch). The Partek Batch Remover that
we used employs a mixed-model ANOVA of the technical
factors to identify and remove these sources of variation.
The variation is reported as the average F ratio, a measure
of the average signal-to-noise ratio of all the computed
variables for each factor. Each component (Batch, Spot or
Array) are compared to the error measurement, normal-
ized to unity for reference.
We averaged all spectra with replicates and performed all
statistical analyses using nonparametric tests: the Mann-
Whitney test to compare 2 groups and the Kruskal-Wallis
test to compare more than 2 groups. A bootstrap method
was used to perform multiple test correction in the statis-
tical tests. The bootstrap is used to determine the proba-
bility of obtaining a particular p-value by chance. Group
labels are randomly re-assigned (with replacement) for a
total of 2,000 iterations of the bootstrap. The bootstrap
method does not assume that tests are independent.
Hierarchical clustering was performed on the peak inten-
sities of the spectra using a Spearman rank dissimilarity
metric with average linkage.
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